126 344

Cited 30 times in

A phase II trial of S-1 monotherapy in metastatic colorectal cancer after failure of irinotecan- and oxaliplatin-containing regimens

 H-C Jeung  ;  S Y Rha  ;  B C Cho  ;  N C Yoo  ;  J K Roh  ;  W J Roh  ;  H C Chung  ;  J B Ahn 
 BRITISH JOURNAL OF CANCER, Vol.95(12) : 1637-1641, 2006 
Journal Title
Issue Date
Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use* ; Camptothecin/administration & dosage ; Camptothecin/analogs & derivatives ; Colorectal Neoplasms/drug therapy* ; Colorectal Neoplasms/pathology ; Colorectal Neoplasms/secondary ; Drug Combinations ; Female ; Humans ; Irinotecan ; Liver Neoplasms/drug therapy* ; Liver Neoplasms/secondary ; Lung Neoplasms/drug therapy* ; Lung Neoplasms/secondary ; Lymphatic Metastasis/pathology ; Male ; Middle Aged ; Neoplasm Recurrence, Local/drug therapy* ; Organoplatinum Compounds/administration & dosage ; Oxaliplatin ; Oxonic Acid/administration & dosage ; Salvage Therapy ; Survival Rate ; Tegafur/administration & dosage ; Treatment Outcome
colorectal adenocarcinoma ; S-1 ; oxaliplatin-resistant ; irinotecan-resistant
This is the first phase II study of S-1 monotherapy for patients with metastatic colorectal cancer after failure of both irinotecan- and oxaliplatin-containing regimens. The initial dose of S-1 was 35 mg m−2, administered twice daily for 14 days every 3 weeks. Treatment was repeated until the occurrence of disease progression. Twenty-eight patients were enrolled. S-1 was administered to 21 patients as third-line therapy and to the remaining seven patients as fourth-line therapy. Of 26 evaluable patients, the overall response rate was 14.3% (95% CI, 0.4–28.1), and the disease control rate was 42.9% (95% CI, 23.3–62.4). With a median follow-up period of 227 days, median time to progression and overall survival duration were 91 and 414 days, respectively. The 1-year survival rate of all patients was 60.7%. There was no grade 4 toxicity. Grade 3 haematological toxicities were documented only in two patients. In conclusion, S-1 shows potential as a salvage regimen in heavily pretreated colorectal cancer patients. The twice-daily dose of 35 mg m−2 was well tolerated and can be used in designing further combination chemotherapy.
Files in This Item:
T200603780.pdf Download
Appears in Collections:
5. Research Institutes (연구소) > Cancer Metastasis Research Center (암전이연구센터) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Roh, Jae Kyung(노재경)
Rha, Sun Young(라선영) ORCID logo https://orcid.org/0000-0002-2512-4531
Ahn, Joong Bae(안중배) ORCID logo https://orcid.org/0000-0001-6787-1503
Yoo, Nae Choon(유내춘)
Chung, Hyun Cheol(정현철) ORCID logo https://orcid.org/0000-0002-0920-9471
Jeung, Hei Cheul(정희철) ORCID logo https://orcid.org/0000-0003-0952-3679
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.